Summary
This multi-centre study investigated tumour heterogeneity of FGFR3 mutations in invasive bladder cancer to clarify the molecular landscape and inform perioperative anti-FGFR3 treatment strategies. The research, published in 2016, involved an international consortium of urologists and molecular pathologists examining mutation patterns across patient cohorts. The findings as suggested by the study design were intended to support clinicians in patient selection and timing of targeted therapies.
UK applicability
Findings are applicable to UK urological oncology and bladder cancer treatment protocols, particularly in stratifying patients for FGFR3-targeted therapies. The multi-centre international design suggests relevance to NHS urology and cancer centres undertaking precision medicine approaches.
Key measures
FGFR3 mutation frequency and spatial distribution within bladder tumours; implications for anti-FGFR3 therapeutic targeting
Outcomes reported
The study examined the prevalence and heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations across tumour samples in invasive bladder cancer patients, as suggested by the title. The research aimed to inform perioperative treatment strategies targeting FGFR3.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.